Anixa Biosciences (ANIX) said Tuesday it has entered into a letter of intent with Verdi Solutions to develop artificial intelligence-guided peptide vaccines, tailored to individual cancer patients.
Under the letter of intent, Anixa has a six-month exclusive right to finalize a transaction for the research, development, and commercialization of Verdi's cancer vaccines.
Anixa and Verdi are targeting to start clinical trials for personalized vaccines in the US, the biotechnology company said.
Verdi is also developing off-the-shelf cancer vaccines, combined with companion diagnostics, Anixa said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。